Antagonist antibodies against GDF-8 and uses therefor
US-8992913-B2 · Mar 31, 2015 · US
US9994641B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9994641-B2 |
| Application number | US-201415107839-A |
| Country | US |
| Kind code | B2 |
| Filing date | Dec 24, 2014 |
| Priority date | Dec 25, 2013 |
| Publication date | Jun 12, 2018 |
| Grant date | Jun 12, 2018 |
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
What the patent document calls the invention.
A short plain-language summary of the technical disclosure.
Who owns or filed the patent and who is credited as inventor.
Filing, priority, publication, and grant dates set the timeline.
The legal scope of protection — read this for what is actually claimed.
Technology tags used to group this patent with similar filings.
Prior art links and similar publications in this corpus.
Official abstract text for this publication.
Disclosed are a novel anti-human transferrin receptor antibody comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 4, 5, 6 and 7 that can pass through the blood-brain barrier, a fusion protein comprising a protein necessary to be brought into function in the central nervous system and the antibody, and method of their production. The fusion protein comprises amino acid sequences of an anti-human transferrin receptor antibody that recognizes an amino acid sequence selected from the group consisting of SEQ ID NOs:1, 2, and 3, and of other protein that is bound thereto on the C-terminal side.
Opening claim text (preview).
The invention claimed is: 1. A single-chain anti-human transferrin receptor antibody comprising an amino acid sequence selected from the group consisting of SEQ ID Nos: 4, 5, 6, and 7. 2. A DNA sequence encoding the antibody according to claim 1 . 3. A fusion protein comprising the antibody according to claim 1 and another protein bound thereto on the C-terminal side. 4. The fusion protein according to claim 3 wherein the another protein is bound to the C-terminal side of the antibody by a linker sequence consisting of 3-50 amino acids. 5. The fusion protein according to claim 3 , wherein said another protein is a lysosomal enzyme. 6. The fusion protein according to claim 5 , wherein the lysosomal enzyme is human iduronate 2-sulfatase. 7. A DNA sequence encoding the fusion protein according to claim 3 . 8. A mammalian expression vector comprising the DNA sequence according to claim 7 . 9. A mammalian cell transformed with the mammalian expression vector according to claim 8 . 10. The cell according to claim 9 , wherein the mammalian cell is a CHO cell.
Iduronate-2-sulfatase (3.1.6.13) · CPC title
from primates, e.g. man · CPC title
against CD71 · CPC title
Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00) · CPC title
Single chain antibody (scFv) · CPC title
Related publications grouped by family.
Answers are generated from the same data shown on this page.